Until recently, RET-selective TKIs were not available, and multitargeted TKIs with anti-RET activity such as cabozantinib and vandetanib were therefore tested in patients with advanced RET fusion-positive (RET+) NSCLC, with modest activity and significant toxicities [12,13,14,15,16,17,18,19,20,21]. Here, RET is linked to non-small cell lung carcinoma.